Rca Laboratory Services, LLC

Rca Laboratory Services, LLC was paid $17.10M by Medicaid between Feb 2018 and Jul 2024, across 82 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 84% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Virginia

Rank by total paid#4 of 78

Median peer was paid$37K

This provider vs. median464×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	16,002	$512K
2019	20,451	$555K
2020	96,896	$3.81M
2021	216,750	$9.12M
2022	86,538	$2.72M
2023	18,053	$331K
2024incomplete	3,193	$44K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	84%	303,860	162,139	$14.31M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	6.4%	32,494	16,195	$1.09M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	3.0%	43,444	29,217	$520K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	2,160	1,812	$161K
87481		<1%	3,573	3,031	$92K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	1,754	1,461	$67K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	812	546	$65K
81226		<1%	340	302	$60K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	3,017	2,683	$57K
82570		<1%	28,823	14,774	$57K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	2,935	2,600	$54K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	719	359	$40K

70 more codes

81225		<1%	332	$39K
87150		<1%	654	$37K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	2,487	$37K
81350		<1%	349	$30K
87511		<1%	1,872	$26K
81227		<1%	341	$23K
81401		<1%	351	$22K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	780	$19K
81231		<1%	284	$18K
81230		<1%	284	$18K
81328		<1%	270	$17K
86803		<1%	1,324	$17K
81105		<1%	242	$14K
81112		<1%	242	$14K
81232		<1%	270	$14K
86704		<1%	1,323	$13K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	480	$13K
81355		<1%	351	$11K
86706		<1%	1,308	$11K
81241		<1%	340	$10K
80053	Comprehensive metabolic panel	<1%	1,895	$10K
87340		<1%	1,318	$10K
81240		<1%	340	$9K
81291		<1%	341	$9K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	86	$8K
87551		<1%	997	$8K
87653		<1%	1,666	$8K
87471		<1%	1,005	$7K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,045	$5K
87500		<1%	650	$5K
87641		<1%	946	$5K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	1,730	$4K
81400		<1%	44	$4K
87486		<1%	195	$3K
82977		<1%	1,030	$3K
83735		<1%	968	$2K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	200	$2K
81003		<1%	1,353	$2K
81479	Unlisted molecular pathology procedure	<1%	411	$1K
87581		<1%	194	$1K
84702		<1%	163	$1K
87563		<1%	266	$1K
87529		<1%	66	$1K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	15	$1K
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	53	$589.15
86780		<1%	33	$283.62
86592		<1%	1,441	$236.04
87640		<1%	124	$208.10
87503		<1%	44	$99.72
80074		<1%	13	$99.41
82565		<1%	32	$73.08
80061	Lipid panel	<1%	78	$46.62
36415	Collection of venous blood by venipuncture	<1%	416	$42.84
85027		<1%	187	$42.31
81001		<1%	105	$33.33
84443	Thyroid stimulating hormone (TSH)	<1%	142	$26.03
87077		<1%	24	$23.77
82247		<1%	86	$18.98
83036	Hemoglobin; glycosylated (A1C)	<1%	22	$9.53
80048	Basic metabolic panel (calcium, ionized)	<1%	29	$8.30
82947		<1%	27	$7.07
84155		<1%	49	$6.61
84075		0%	27	$0.00
82607		0%	17	$0.00
86343		0%	21	$0.00
82040		0%	27	$0.00
84450		0%	27	$0.00
87634		0%	54	$0.00
84439		0%	39	$0.00
84460		0%	27	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMCCLURE, KEVIN (CFO)